Logo image of XRTX.CA

XORTX THERAPEUTICS INC (XRTX.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:XRTX - CA98420Q3061 - Common Stock

0.81 CAD
+0.03 (+3.85%)
Last: 1/16/2026, 7:00:00 PM
Fundamental Rating

1

Taking everything into account, XRTX scores 1 out of 10 in our fundamental rating. XRTX was compared to 35 industry peers in the Pharmaceuticals industry. The financial health of XRTX is average, but there are quite some concerns on its profitability. XRTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • XRTX had negative earnings in the past year.
  • In the past year XRTX has reported a negative cash flow from operations.
  • XRTX had negative earnings in each of the past 5 years.
  • XRTX had a negative operating cash flow in each of the past 5 years.
XRTX.CA Yearly Net Income VS EBIT VS OCF VS FCFXRTX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -69.13%, XRTX is doing worse than 77.14% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -98.46%, XRTX is doing worse than 68.57% of the companies in the same industry.
Industry RankSector Rank
ROA -69.13%
ROE -98.46%
ROIC N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
XRTX.CA Yearly ROA, ROE, ROICXRTX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • XRTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XRTX.CA Yearly Profit, Operating, Gross MarginsXRTX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

  • XRTX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for XRTX has been reduced compared to 5 years ago.
  • The debt/assets ratio for XRTX is higher compared to a year ago.
XRTX.CA Yearly Shares OutstandingXRTX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XRTX.CA Yearly Total Debt VS Total AssetsXRTX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • XRTX has an Altman-Z score of -9.48. This is a bad value and indicates that XRTX is not financially healthy and even has some risk of bankruptcy.
  • XRTX has a worse Altman-Z score (-9.48) than 80.00% of its industry peers.
  • XRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.48
ROIC/WACCN/A
WACCN/A
XRTX.CA Yearly LT Debt VS Equity VS FCFXRTX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

  • XRTX has a Current Ratio of 1.62. This is a normal value and indicates that XRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • XRTX's Current ratio of 1.62 is in line compared to the rest of the industry. XRTX outperforms 51.43% of its industry peers.
  • XRTX has a Quick Ratio of 1.62. This is a normal value and indicates that XRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • XRTX has a better Quick ratio (1.62) than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
XRTX.CA Yearly Current Assets VS Current LiabilitesXRTX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

  • The earnings per share for XRTX have decreased strongly by -1213.33% in the last year.
EPS 1Y (TTM)-1213.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XRTX.CA Yearly EPS VS EstimatesXRTX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • XRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year XRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XRTX.CA Price Earnings VS Forward Price EarningsXRTX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XRTX.CA Per share dataXRTX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for XRTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

XORTX THERAPEUTICS INC

TSX-V:XRTX (1/16/2026, 7:00:00 PM)

0.81

+0.03 (+3.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners1.45%
Inst Owner ChangeN/A
Ins Owners1.87%
Ins Owner ChangeN/A
Market Cap5.64M
Revenue(TTM)N/A
Net Income(TTM)-1.94M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.05
P/tB 2.28
EV/EBITDA N/A
EPS(TTM)-0.66
EYN/A
EPS(NY)-2.16
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS0.39
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.13%
ROE -98.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z -9.48
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)48.3%
Cap/Depr(5y)87.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1213.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.88%
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.46%
OCF growth 3YN/A
OCF growth 5YN/A

XORTX THERAPEUTICS INC / XRTX.CA FAQ

What is the ChartMill fundamental rating of XORTX THERAPEUTICS INC (XRTX.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to XRTX.CA.


What is the valuation status of XORTX THERAPEUTICS INC (XRTX.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to XORTX THERAPEUTICS INC (XRTX.CA). This can be considered as Overvalued.


Can you provide the profitability details for XORTX THERAPEUTICS INC?

XORTX THERAPEUTICS INC (XRTX.CA) has a profitability rating of 0 / 10.


What is the financial health of XORTX THERAPEUTICS INC (XRTX.CA) stock?

The financial health rating of XORTX THERAPEUTICS INC (XRTX.CA) is 5 / 10.


What is the earnings growth outlook for XORTX THERAPEUTICS INC?

The Earnings per Share (EPS) of XORTX THERAPEUTICS INC (XRTX.CA) is expected to decline by -11.64% in the next year.